TL;DR
This study investigates the molecular mechanisms behind Hui Yang Jiu Ji (HYJJ), a traditional Chinese medicine, in treating chronic heart failure (CHF) in rats. Researchers found that HYJJ not only improves cardiac function and reduces heart damage but also modulates the expression of long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), suggesting a complex regulatory network underlying its therapeutic effects.
What Problem Does This Paper Address?
Chronic heart failure (CHF) is a debilitating condition with high mortality, posing a significant healthcare burden. While traditional Chinese medicines like Hui Yang Jiu Ji (HYJJ) have been used for centuries to treat various ailments, including heart conditions, their precise molecular mechanisms remain largely unknown. Doxorubicin (DOX) is a common chemotherapy drug that can induce cardiotoxicity, leading to CHF. This paper aims to elucidate how HYJJ exerts its protective effects against DOX-induced CHF by exploring its impact on the intricate interplay of lncRNAs and miRNAs within the heart.
Methods
The study employed a multi-pronged approach:
- Animal Model: A rat model of CHF was established using doxorubicin (DOX) administration.
- Cardioprotective Assessment: Cardiac function was evaluated using echocardiography (measuring LVIDd, LVIDs, EF, and FS). Myocardial injury was assessed through HE staining and ELISA for cardiac injury markers (cTn-I and NT-proBNP). Myocardial apoptosis was investigated using TUNEL assays and Western blotting for cleaved caspase-3 (c-caspase 3).
- Transcriptome Sequencing: High-throughput RNA sequencing was performed on myocardial tissues to identify differentially expressed lncRNAs and miRNAs in control, CHF, and HYJJ-treated groups.
- Bioinformatics Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to understand the biological processes, cellular components, molecular functions, and signaling pathways affected by HYJJ.
- lncRNA-miRNA Interaction Prediction: Computational methods were used to predict potential interactions between identified lncRNAs and miRNAs.
Datasets
Not discussed in the paper. The study utilized RNA sequencing data generated from rat myocardial tissues.
Key Insights and Ideas
- HYJJ as a Cardiac Protector: HYJJ demonstrates significant cardioprotective effects, not only by improving cardiac function and reducing myocardial injury but also by actively inhibiting apoptosis in the heart. This suggests a multi-faceted therapeutic action.
- Complex lncRNA-miRNA Network: The study highlights that HYJJ's effects are mediated through a complex regulatory network involving both lncRNAs and miRNAs. The significant number of differentially expressed lncRNAs and miRNAs points to a broad impact on gene expression regulation.
- Shared Pathways, Unique Signatures: While some pathways, like Adrenergic signaling in cardiomyocytes and Cushing's syndrome, were commonly affected by both lncRNA and miRNA dysregulation, the specific enrichment patterns suggest distinct roles for each molecule class in HYJJ's action.
- Novel Pathway Identification: The identification of a potential MSTRG.598.1/Lilrb2 pathway as a target of HYJJ treatment is a novel finding, opening avenues for further investigation into specific molecular interactions. Lilrb2's known role in myocardial infarction suggests its relevance.
Key Results
- Improved Cardiac Function: HYJJ treatment significantly improved echocardiographic parameters (LVIDd, LVIDs, EF, FS) in DOX-induced CHF rats.
- Reduced Myocardial Injury: HE staining showed reduced myocardial fiber necrosis, and ELISA revealed significantly lower levels of cTn-I and NT-proBNP in HYJJ-treated rats compared to CHF rats.
- Inhibited Apoptosis: TUNEL assays and Western blot analysis confirmed that HYJJ significantly reduced myocardial apoptosis by downregulating c-caspase 3 expression.
- Extensive Transcriptomic Changes: RNA sequencing identified 475 differentially expressed lncRNAs and 491 differentially expressed miRNAs in CHF rats compared to controls. HYJJ treatment further modulated these expressions.
- Pathway Enrichment: Key pathways affected by HYJJ included PI3K-Akt signaling (for lncRNAs) and Adrenergic signaling in cardiomyocytes, Cushing's syndrome, and Type II diabetes mellitus (for both lncRNAs and miRNAs).
- Potential lncRNA-miRNA Interaction: A single lncRNA-miRNA pair, MSTRG.598.1 and Lilrb2, was identified as a potential trans-acting interaction in the HYJJ-treated group.
Limitations and Future Work
The authors acknowledge that this is a pilot study with a limited sample size, which may have prevented the detection of more subtle differences. They emphasize the need for more in-depth investigations to validate the identified molecular mechanisms, particularly the MSTRG.598.1/Lilrb2 pathway. Future work will focus on further confirming these findings and exploring the precise roles of specific lncRNAs and miRNAs in HYJJ's therapeutic effects on CHF.
Summary updated